Omnicell says advance services to drive profitable growth in long-run: Investor Day

Sep. 20, 2022 4:37 PM ETOmnicell, Inc. (OMCL)By: Shweta Agarwal, SA News Editor
  • Omnicell (NASDAQ:OMCL) sees its transformation to advance service business model to reap benefits in the long-run with contribution of ~20% to 30% of total revenue by 2025, the medication management company said at 2022 Investor Day.
  • The company noted new long-term gross margin targets for SaaS and subscription software is estimated to range between 70% to 75%, and and tech-enabled services gross margin of 50% to 55%.
  • With total addressable market of $90B, Omnicell highlighted its presence in about 80% of all retail pharmacies in the U.S.
  • Reaffirmed Guidance: The company expects its total revenue of $1.9-$2B, representing a 14% to 15% total revenue CAGR; Non-GAAP gross margin of 52% to 53%.
  • Non-GAAP EBITDA margin of approximately 23%, reflecting the impact of the current inflationary environment.
  • SaaS and subscription software gross margin of 65% to 70%; and Tech-enabled services gross margin of 40%.
  • Earlier: Omnicell reports Q2 earnings miss; reaffirms FY22 guidance and issues Q3 outlook

Recommended For You

Comments

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.